Clinical trial
Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer
NCT00004163 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00004163 |
|---|---|
| Title | Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer |
| Official title | Herceptin In Patients With Advanced or Metastatic Salivary Gland Carcinomas |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Drug |
| Interventions | Trastuzumab |
| Enrollment | 14 |
| Start date | Oct 1, 1999 |
| Primary completion | Sep 1, 2001 |
| Completion | Sep 1, 2001 |
| First posted | Mar 15, 2004 |
| Last update posted | Apr 18, 2017 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: